Waldenström’s macroglobulinemia

Stephen Maxted Ansell, Lucy S. Hodge, Suzanne R. Hayman

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Waldenström’s macroglobulinemia (WM) is a B-cell lymphoproliferative disorder defined by a lymphoplasmacytic infiltration in the bone marrow or lymphatic tissue and a monoclonal immunoglobulin M (IgM) protein in the serum [1, 2]. The infiltration of the bone marrow and extramedullary sites by malignant B-cells, as well as elevated IgM levels, accounts for the symptoms associated with this disease. This may result in patients developing constitutional symptoms, pancytopenia, organomegaly, neuropathy, symptoms associated with immunoglobulin deposition, or hyperviscosity [3, 4]. There is significant heterogeneity, however, in the symptoms with which patients present. While some patients present with the symptoms listed above, many are asymptomatic at the time of diagnosis. Waldenström’s macroglobulinemia remains incurable with current therapy with a median survival for symptomatic patients of approximately 8 years [5]. However, because many patients are diagnosed with this disease at an advanced age, approximately half of the patients die from causes unrelated to Waldenström’s macroglobulinemia. Due to the incurable nature of the disease, the heterogeneity of clinical presentation, as well as the comorbid conditions and competing causes of death, the decision to treat patients and the choice of treatment can be rather complex. A number of consensus meetings have listed reasonable treatment options [6–8], but the treating physician is still faced with a difficult treatment decision in a patient with an uncommon disease.

Original languageEnglish (US)
Title of host publicationMultiple Myeloma: Diagnosis and Treatment
PublisherSpringer New York
Pages289
Number of pages1
ISBN (Print)9781461485209, 9781461485193
DOIs
StatePublished - Jan 1 2014

Fingerprint

Waldenstrom Macroglobulinemia
Immunoglobulin M
B-Lymphocytes
Bone Marrow
Pancytopenia
Lymphoproliferative Disorders
Lymphoid Tissue
Therapeutics
Immunoglobulins
Blood Proteins
Cause of Death
Physicians
Bone and Bones
Survival

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Ansell, S. M., Hodge, L. S., & Hayman, S. R. (2014). Waldenström’s macroglobulinemia. In Multiple Myeloma: Diagnosis and Treatment (pp. 289). Springer New York. https://doi.org/10.1007/978-1-4614-8520-9_24

Waldenström’s macroglobulinemia. / Ansell, Stephen Maxted; Hodge, Lucy S.; Hayman, Suzanne R.

Multiple Myeloma: Diagnosis and Treatment. Springer New York, 2014. p. 289.

Research output: Chapter in Book/Report/Conference proceedingChapter

Ansell, SM, Hodge, LS & Hayman, SR 2014, Waldenström’s macroglobulinemia. in Multiple Myeloma: Diagnosis and Treatment. Springer New York, pp. 289. https://doi.org/10.1007/978-1-4614-8520-9_24
Ansell SM, Hodge LS, Hayman SR. Waldenström’s macroglobulinemia. In Multiple Myeloma: Diagnosis and Treatment. Springer New York. 2014. p. 289 https://doi.org/10.1007/978-1-4614-8520-9_24
Ansell, Stephen Maxted ; Hodge, Lucy S. ; Hayman, Suzanne R. / Waldenström’s macroglobulinemia. Multiple Myeloma: Diagnosis and Treatment. Springer New York, 2014. pp. 289
@inbook{6f4830b5c150465fb2e42c3645558c32,
title = "Waldenstr{\"o}m’s macroglobulinemia",
abstract = "Waldenstr{\"o}m’s macroglobulinemia (WM) is a B-cell lymphoproliferative disorder defined by a lymphoplasmacytic infiltration in the bone marrow or lymphatic tissue and a monoclonal immunoglobulin M (IgM) protein in the serum [1, 2]. The infiltration of the bone marrow and extramedullary sites by malignant B-cells, as well as elevated IgM levels, accounts for the symptoms associated with this disease. This may result in patients developing constitutional symptoms, pancytopenia, organomegaly, neuropathy, symptoms associated with immunoglobulin deposition, or hyperviscosity [3, 4]. There is significant heterogeneity, however, in the symptoms with which patients present. While some patients present with the symptoms listed above, many are asymptomatic at the time of diagnosis. Waldenstr{\"o}m’s macroglobulinemia remains incurable with current therapy with a median survival for symptomatic patients of approximately 8 years [5]. However, because many patients are diagnosed with this disease at an advanced age, approximately half of the patients die from causes unrelated to Waldenstr{\"o}m’s macroglobulinemia. Due to the incurable nature of the disease, the heterogeneity of clinical presentation, as well as the comorbid conditions and competing causes of death, the decision to treat patients and the choice of treatment can be rather complex. A number of consensus meetings have listed reasonable treatment options [6–8], but the treating physician is still faced with a difficult treatment decision in a patient with an uncommon disease.",
author = "Ansell, {Stephen Maxted} and Hodge, {Lucy S.} and Hayman, {Suzanne R.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1007/978-1-4614-8520-9_24",
language = "English (US)",
isbn = "9781461485209",
pages = "289",
booktitle = "Multiple Myeloma: Diagnosis and Treatment",
publisher = "Springer New York",

}

TY - CHAP

T1 - Waldenström’s macroglobulinemia

AU - Ansell, Stephen Maxted

AU - Hodge, Lucy S.

AU - Hayman, Suzanne R.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Waldenström’s macroglobulinemia (WM) is a B-cell lymphoproliferative disorder defined by a lymphoplasmacytic infiltration in the bone marrow or lymphatic tissue and a monoclonal immunoglobulin M (IgM) protein in the serum [1, 2]. The infiltration of the bone marrow and extramedullary sites by malignant B-cells, as well as elevated IgM levels, accounts for the symptoms associated with this disease. This may result in patients developing constitutional symptoms, pancytopenia, organomegaly, neuropathy, symptoms associated with immunoglobulin deposition, or hyperviscosity [3, 4]. There is significant heterogeneity, however, in the symptoms with which patients present. While some patients present with the symptoms listed above, many are asymptomatic at the time of diagnosis. Waldenström’s macroglobulinemia remains incurable with current therapy with a median survival for symptomatic patients of approximately 8 years [5]. However, because many patients are diagnosed with this disease at an advanced age, approximately half of the patients die from causes unrelated to Waldenström’s macroglobulinemia. Due to the incurable nature of the disease, the heterogeneity of clinical presentation, as well as the comorbid conditions and competing causes of death, the decision to treat patients and the choice of treatment can be rather complex. A number of consensus meetings have listed reasonable treatment options [6–8], but the treating physician is still faced with a difficult treatment decision in a patient with an uncommon disease.

AB - Waldenström’s macroglobulinemia (WM) is a B-cell lymphoproliferative disorder defined by a lymphoplasmacytic infiltration in the bone marrow or lymphatic tissue and a monoclonal immunoglobulin M (IgM) protein in the serum [1, 2]. The infiltration of the bone marrow and extramedullary sites by malignant B-cells, as well as elevated IgM levels, accounts for the symptoms associated with this disease. This may result in patients developing constitutional symptoms, pancytopenia, organomegaly, neuropathy, symptoms associated with immunoglobulin deposition, or hyperviscosity [3, 4]. There is significant heterogeneity, however, in the symptoms with which patients present. While some patients present with the symptoms listed above, many are asymptomatic at the time of diagnosis. Waldenström’s macroglobulinemia remains incurable with current therapy with a median survival for symptomatic patients of approximately 8 years [5]. However, because many patients are diagnosed with this disease at an advanced age, approximately half of the patients die from causes unrelated to Waldenström’s macroglobulinemia. Due to the incurable nature of the disease, the heterogeneity of clinical presentation, as well as the comorbid conditions and competing causes of death, the decision to treat patients and the choice of treatment can be rather complex. A number of consensus meetings have listed reasonable treatment options [6–8], but the treating physician is still faced with a difficult treatment decision in a patient with an uncommon disease.

UR - http://www.scopus.com/inward/record.url?scp=84956486580&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84956486580&partnerID=8YFLogxK

U2 - 10.1007/978-1-4614-8520-9_24

DO - 10.1007/978-1-4614-8520-9_24

M3 - Chapter

AN - SCOPUS:84956486580

SN - 9781461485209

SN - 9781461485193

SP - 289

BT - Multiple Myeloma: Diagnosis and Treatment

PB - Springer New York

ER -